Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So....when and where is the 2023 shareholder meeting?
One additional risk shareholders have here is the stock staying below one dollar. The NASDAQ could decide to delist it soon. Then it's a matter of looking at how many other companies have ruined themselves by effecting reverse splits. I am confident that a journey into an actual Phase III test would help the company's stock rise above a dollar and stay there. Aptose has had opportunities to enter a Phase III portal over the last few years but has opted to stay stuck in Phase 1/2. Time is of the essence these days.
I can't blame politicians of either party for the current banking debacle. Tech companies screwed up by exceeding the FDIC insurance limits. The bank screwed up assuming maximum interest rate risk by buying 30 year Treasuries with interest rates at all time lows. It isn't rocket science or worthy of Congressional scrutiny unless the entire small banking system is full of incompetent investment officers. Let's hope AUPH didn't have much "over-exposure".
I never have posted on this board but did watch this stock trade at $50 per share based solely on the hype associated with one individual. Does anyone think there is value at .35 and, if so, from what source?
The company purposely has relegated itself to years of Phase 1/2 testing and can't seem to get out of its own way these days. Trying to establish a higher dosage every time it reached a milestone has been time consuming and anti-climactic. Now it seems that the higher doses, once revered as effective, are being removed? Comments, please.
Not sure how CRs could be designated as "inferior".
Are the side effect profiles meaningful or are they in such a small % occurrence that they are not going to factored into the process?
Either or both.....getting trials to more advanced stages has been a major obstacle.
It deserves to be best in class given the two years extra time the company took trying to reach a max dosage.
Interesting. Thanks for the info. Did they run into a brick wall at 200 mg? They kept wanting to ramp it up at each mg conclusion to see how far they could go.
Okay, you two. Thanks for being on board here. Do you have any indication that APTO actually has decided on a dosage with which the company is confident and comfortable running to the finish line?
He will at the next annual meeting, I guarantee it.
Happy New Year, everyone. 2023 will be an improvement. It has to be. I have had one lingering thought (just one...ha) all year long: This potential patent issue would have been well known by Master Glickman "way back when". I can't help but believe he would have dealt with it at the time had there been anything to it. So....I remain in the camp that this thing is, hopefully, "much ado about nothing". That doesn't mean Aurinia wouldn't compromise just to save litigation fees. Companies do that all the time. Do we have any tentative dates when this thing will be decided?
Keep in mind that people are being treated who are in advanced stages of AML. 239 is working where previously applied treatments did not work. Some people are going to be too close to passing to benefit from any form of treatment. The commentary indicated that 239 was NOT responsible for a patient passing. My contention is that the company still needs to determine the ideal dosage and move forward toward FDA review.
The company doesn't seem to be participating in the normal fanfare for its industry this year: Biotech conferences? Insider buying? Stock options granted at considerably higher prices than the current trading price? Hmmmmm
Well.....another M.D. with serious credentials has been hired by Aptose. Dr. Seizinger has the Harvard/Bristol Myers background. Maybe he has a little more "pull" concerning getting 239 to market.....or instigating a merger.
The company would have to receive some sort of positive FDA information for 239 in order to get its stock out from under the $1.00 watermark. An FDA approval means that the company actually settled on a dosage and ramped up testing into a Phase III event. That's not happening. This company is destined to waste years of valuable time trying to find a side-effect breaking point for 239 instead of working toward FDA approval with an already-existing time tested dosage.
That premise might be a winner. Vocs is unique to LN and is its lead product, so how can it get a dosage question for LN? Me thinks Sun is really overstepping its boundaries.
Seeking Alpha put out a fairly negative article on the company. I would be interested to see if any of you have a better, more enlightened opinion than S.A.
Trying to keep the horse before the cart, it would make sense to me that these people were brought on board only after Glickman's greediness in a down market cycle failed once again and caused the company to have to ramp up its GIA attempts.
Well....I see where LaJolla Pharmaceuticals announced it's getting bought out. LaJolla's lupus drug failure was announced thirteen years ago. The article also announced the failure of Genentech and Biogen to come up with a suitable treatment. Interesting.
Hopefully the publicity from a Merck/Seagen deal will get the industry moving again.
Big pharma loves to buy small companies in early phases of testing products. It's a leverage game. They don't have to shell out much money, and their own experienced staff can bring a product to fruition. Many times, however, those big boys are left holding the bag. Earlier research was faulty, and the FDA was quick to turn up its nose. I just don't get the big boys who have been unable to process a lupus nephritis product. Sure...they're going to spend a bunch of money for Aurinia, but how much did they spend creating failed enterprise?
My sentiments, exactly.
Gilead has underperformed for so long, given the size of the company as well, that I could encourage Bill Ackman to make a run at it.
I see you have swung over to the AUPH page. Shareholder activist? I would love to see Bill Ackman go after Gilead Sciences.
Well...another year has gone by. The stock is below 50 cents. Is there anything at all related to clinical trials in the U.S. going on?
The problem has been the continuous search for successful larger dosing within the same Phase 1/2 testing mechanism that has been in place for years. When is the company going to actually move ahead with a Phase III launch since it has obtained Fast Track review status?
As solid as we know this product is, our CEO's behavior over the past six months has earned him an obligation to answer a few tough questions at the shareholder meeting.
I just read through the material to be covered at the annual meeting. Most of it revolves around compensation. There doesn't seem to be much discussion, let alone answers, of the tough questions that could be asked by shareholders at this meeting. Do any members of this IHUB space plan to attend?
When an industry like biotech gets into normal malaises, a merger along the way helps investors re-focus on the longer term instead of next week. Maybe we'll see a couple of them now that we have experienced dramatic corrections in prices across the board.
2 1/2 million shares in the first hour
Geezil......people are getting antsy. Have there been any 13ds filed in the last couple of months?
Geezil......people are getting antsy. Have there been any 13ds filed in the last couple of months?
.......just wondering what's taking Lilly so long?
Yesterday, under the cover of a market rout, a few institutions could have come in and bought a few million shares without attracting any attention. The upside volume yesterday afternoon was huge.
If I had a merger in the wings, I certainly would NOT announce it at someone's else's conference.
A pretty stellar day today given the overall market and bunch of other biotechs being down. Up 97 cents on about 2.7 million shares.
The Wainwright Conference begins tomorrow, and the text says Aurinia's presentation should be available at 3:00 P.M. EDT.
Aurinia is speaking at two investor conferences next week. It will be interesting to find out how the company fielded the obvious, Bloomberg created, potential merger questions.